In the MAVA-LTE and EXPLORER LTE studies, mavacamten is predicted to reduce left ventricular outflow tract obstruction and potentially reduce heart thickening in patients with symptomatic obstructive hypertrophic cardiomyopathy. touchCARDIO spoke to Dr Florian Rader (Cedars-Sinai Medical Center, Los Angeles, CA, USA) to discusses the interim results of the MAVA-LTE study and the clinical implications […]

The IVVE study is a randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events. It was delightful to speak with Prof Mark Loeb (McMaster University, Hamilton, Canada) about his presentation at the American College of Cardiology Annual Meeting 2022. Questions: What is known about the effects of the […]

Data from the American College of Cardiology (ACC) Global Heart Attack Treatment Initiative (GHATI) offers a novel insights into ST segment elevation myocardial infarction (STEMI) care in low-middle income countries. touchCARDIO spoke to Prof César Herrera (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss his presentation at the ACC Annual Meeting 2022 entitled […]

The PROTECT Trial puts into question hypothermia prevention at non-cardiac surgery and assessed whether patients’ body temperatures could be kept at 35.5°C or should be maintained closer to 37 degrees. touchCARDIO spoke to Prof Daniel Sessler (Cleveland Clinic, Cleveland, OH, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled: […]

Several smart, connected and direct-to-consumer wearable devices capable of detecting cardiac arrhythmias have proliferated in the marketplace in the last decade. Increasingly, these devices are being marketed as “medical grade” in addition to “wellness” devices.1 New iterations of smartwatch and smartphone technology incorporate biosensors and advanced artificial intelligence (AI) algorithms equipped to diagnose cardiac arrhythmias; examples […]

Available evidence from randomized studies suggests that most bifurcation lesions are best managed with a provisional stenting (PS) approach, as this is associated with fewer complications, simpler procedures and better outcomes, compared with elective double stenting.1–6 However, the Achilles’ heel of single-stent strategies is represented by a higher risk of suboptimal result on the side branch, […]

The first coronary stent was implanted by Sigwart and Puel in 1986.1 Coronary stents were initially used to treat failure of balloon angioplasty treatment, i.e. as bail-out for acute vessel closure (due to dissections) or restenosis (due to elastic recoil). After the BENESTENT and STRESS landmark randomized trials, the routine use of coronary stents for percutaneous […]

The true epidemiology of out-of-hospital cardiac arrest (OHCA) is difficult to define, with wide variations in reporting, management and outcomes worldwide.1,2 In Europe, the incidence of OHCA is estimated to be between 67 and 170 per 100,000 people and it continues to be a major public health challenge that is reliant on multiple links in a […]